To evaluate the potential of this group of drug candidates as therapeutic agents for cholangiocarcinoma, we began by evaluating their cytotoxic potential in IL-6 producing cholangiocarcinoma cell lines. This evidence concerns the gene IL6 and cholangiocarcinoma.